\n Data tracked by StockTitan Argus<\/a> on the day of publication. \n <\/p>\n
\n Sexual health market size
\n CHF 1.1 bn
\n
\n Global sexual health market segment referenced in assay launch
\n
\n <\/p>\n
\n Market growth rate
\n 11%
\n
\n Annual growth rate of global sexual health segment
\n
\n <\/p>\n
\n Vaginitis growth rate
\n 26%
\n
\n Yearly growth rate of vaginitis segment within sexual health
\n
\n <\/p>\n
\n Bacterial vaginosis prevalence
\n 25%
\n
\n Women of reproductive age impacted by bacterial vaginosis
\n
\n <\/p>\n
\n Candida vaginitis incidence
\n 75%
\n
\n Women experiencing candida vaginitis at least once in lifetime
\n
\n <\/p>\n
\n Median follow-up
\n 35.1 months
\n
\n Phase III STARGLO three-year follow-up duration
\n
\n <\/p>\n
\n Overall survival benefit
\n 25.5 vs 12.5 months
\n
\n OS Columvi+GemOx vs R-GemOx in STARGLO study
\n
\n <\/p>\n
\n Progression-free survival
\n 20.4 vs 5.5 months
\n
\n PFS Columvi+GemOx vs R-GemOx in STARGLO study
\n
\n <\/p>\n
\n $58.61
\n Last Close
\n <\/p>\n
\n Volume
\n Volume 4,598,153 is 1.76x the 20-day average of 2,619,116.
\n
\n high
\n
\n <\/p>\n
\n Technical
\n Price 50.02 is above the 200-day MA at 41.66 and within 1.28% of the 52-week high 50.67.
\n <\/p>\n
RHHBY gained 3.55% while close peers showed mixed, mostly small moves (from -1.9% to 0.13%), suggesting a stock-specific reaction to the diagnostic launch.<\/p>\n
Pattern Detected<\/p>\n Recent positive clinical and regulatory updates often saw slight negative price reactions, indicating a tendency toward divergence, with only one event showing aligned upside.<\/p>\n Recent Company History<\/p>\n This announcement adds to a series of positive updates for Roche in early December 2025. Alongside this CE Marked vaginitis PCR assay, the company reported European Commission approval for Gazyva\/Gazyvaro in lupus nephritis and multiple Lunsumio lymphoma data readouts, plus three-year survival data from the phase III STARGLO study. Despite generally favorable clinical and regulatory news, several of these prior events saw modest negative price reactions, making today\u2019s move toward the 52-week high stand out versus recent patterns.<\/p>\n
“Roche launches new PCR test to help improve diagnostic accuracy…”<\/p>\n PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably \u2014 think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.<\/p>\n
<\/p>\n
“Roche … announced today the CE Mark for its cobas BV\/CV…”<\/p>\n A CE mark is a regulatory stamp placed on products to show they meet the European Union\u2019s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs\u2014think of it as a passport that lets a product enter a large market.<\/p>\n
<\/p>\n
“detection of bacteria associated with bacterial vaginosis and yeast…”<\/p>\n An imbalance of the natural bacterial community in the vagina that can cause abnormal discharge, odor, and discomfort; it is not always an infection in the usual sense but a shift in which species dominate, similar to weeds overtaking a garden. Investors care because it is a common, recurring condition that drives demand for diagnostics, treatments and clinical trials, can affect regulatory reviews and labeling, and influences revenue and risk for companies developing products targeting women’s reproductive health.<\/p>\n
<\/p>\n
“bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis.”<\/p>\n Candida vaginitis is a common vaginal infection caused by an overgrowth of Candida yeast, producing itching, discharge, and irritation. For investors, it matters because its frequency and treatment options drive demand for prescription drugs, over\u2011the\u2011counter remedies, diagnostics and related health services; think of it like a recurring maintenance issue that determines how much customers and health systems will spend on products and innovation in women’s health.<\/p>\n
<\/p>\n
“BV and CV infections are also associated with an increased risk of having a sexually transmitted infection…”<\/p>\n A sexually transmitted infection is an infection passed between people through sexual contact, caused by bacteria, viruses, or parasites; think of it like catching an illness from close personal contact. Investors care because rates of these infections drive demand for testing, treatments, vaccines and public-health programs, influence regulatory approvals and reimbursement, and can affect costs for insurers and employers\u2014so changes can meaningfully alter revenue and risk for healthcare-related companies.<\/p>\n
<\/p>\n AI-generated analysis. Not financial advice.<\/p>\n
Basel, 9 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY<\/a>) announced today the CE Mark for its cobas\u00ae BV\/CV (Bacterial Vaginosis\/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube.<\/p>\n Clinicians typically rely on microscopy, pH testing, and clinical observation to diagnose BV and CV, which present with non-specific symptoms. These methods can deliver inaccurate results, leading to delays in treatment or prescription of unsuitable therapies. The cobas BV\/CV assay resolves this challenge by delivering accurate and specific results, allowing healthcare professionals to deliver targeted therapies to patients more quickly. <\/p>\n \u201cThe cobas BV\/CV assay protects women from the risks of delayed or incorrect treatment, leading to faster relief from symptoms and a reduced likelihood of serious future complications,\u201d said Matt Sause, CEO of Roche Diagnostics. \u201cAt the same time, it improves efficiency for healthcare services by accurately identifying the most common causes of inflammation or infection in a single test.\u201d<\/p>\n Bacterial vaginosis impacts approximately 25% of women of reproductive age2, while up to 75% of women experience candida vaginitis at least once in their lifetime3. Vaginal symptoms are one of the most common reasons women visit the doctor each year. Diagnosis of these conditions can be challenging as symptoms are often non-specific, and traditional testing methods, such as microscopy, lack precision. Causing uncomfortable and sometimes distressing symptoms such as itching, burning, discharge, and irritation,\u00a0 BV and CV infections are also associated with an increased risk of having a sexually transmitted infection (STI).4<\/p>\n The global sexual health market segment is valued at CHF 1.1 bn, with an annual growth rate of 11%. Of this market segment, vaginitis is the primary growth driver with a yearly growth rate of 26%.5 The cobas BV\/CV assay further expands Roche Diagnostics\u2019 established sexual health portfolio. By enabling testing for BV and CV alongside a broad range of sexually transmitted infections, including Chlamydia, Gonorrhoea, Trichomonas, and Mycoplasma genitalium, using the same sample, the assay enhances the capabilities of the cobas 5800\/6800\/8800 systems. This streamlined approach supports sexual health clinics, hospitals, and laboratories by delivering faster, more efficient workflows, while also ensuring that patients benefit from accurate diagnosis and timely care. <\/p>\n The cobas BV\/CV assay is now available in countries accepting the CE Mark.<\/p>\n About Roche In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. <\/p>\n Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. <\/p>\n For more information, please visit www.roche.com<\/a>.<\/p>\n All trademarks used or mentioned in this release are protected by law.<\/p>\n References Roche Global Media Relations Hans Trees, PhD \u00a0<\/p>\n Nathalie Altermatt \u00a0<\/p>\n Simon Goldsborough \u00a0<\/p>\n Kirti Pandey \u00a0<\/p>\n Dr Rebekka Schnell Roche Investor Relations<\/p>\n Dr Bruno Eschli \u00a0<\/p>\n Dr Birgit Masjost Investor Relations North America<\/p>\n Loren Kalm
\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n Dec 09
\n
\n
\n Diagnostic launch<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -0.4%
\n
\n
\n
\n
\n
\n CE Mark and launch of cobas BV\/CV vaginitis PCR assay.
\n
\n
\n
\n
\n Dec 09
\n
\n
\n Drug approval EU<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -0.4%
\n
\n
\n
\n
\n
\n European Commission approval of Gazyva\/Gazyvaro for lupus nephritis.
\n
\n
\n
\n
\n Dec 08
\n
\n
\n Clinical data Lunsumio<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -0.4%
\n
\n
\n
\n
\n
\n Lunsumio combinations showing strong responses and survival data in lymphomas.
\n
\n
\n
\n
\n Dec 08
\n
\n
\n Clinical data Lunsumio<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -0.4%
\n
\n
\n
\n
\n
\n Genentech Lunsumio data in earlier lymphoma treatment lines at ASH 2025.
\n
\n
\n
\n
\n Dec 08
\n
\n
\n Phase III update<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +0.8%
\n
\n
\n
\n Three-year STARGLO data showing longer OS and PFS with Columvi combo.
\n
\n
\n
\n
<\/p>\n
\n This announcement highlighted Roche\u2019s CE Marked cobas BV\/CV PCR assay, which targets infectious causes of vaginitis and taps into a sexual health market valued at CHF 1.1 bn with 11% annual growth and a vaginitis segment growing 26% yearly. It fits alongside recent positive clinical and regulatory updates in oncology and autoimmune disease. Investors may watch future adoption of the assay on cobas systems, additional regulatory milestones, and how vaginal infection testing contributes to Roche Diagnostics\u2019 broader growth profile.
\n <\/p>\n
\n
\n pcr
\n
\n medical
\n
\n
<\/p>\n
\n
\n ce mark
\n
\n regulatory
\n
\n
<\/p>\n
\n
\n bacterial vaginosis
\n
\n medical
\n
\n
<\/p>\n
\n
\n candida vaginitis
\n
\n medical
\n
\n
<\/p>\n
\n
\n sexually transmitted infection
\n
\n medical
\n
\n
<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 12\/09\/2025 – 01:10 AM
\n
\n
\n The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis.\u00a0The test will help improve diagnostic accuracy for millions of women1 affected by vaginitis annually, delivering more accurate and specific results.This test offers faster diagnosis by using a single vaginal swab for broader sexual health testing, eliminating the need for an additional sample. <\/p>\n
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world\u2019s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.<\/p>\n
[1] Hildebrand JP, Carlson K, Kansagor AT. Vaginitis. National Library of Medicine. 2025 Jan 19, PMID: 29262024\u00a0 <\/a>Bookshelf ID: NBK470302
[2] Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019 May;46(5):304-311. doi: 10.1097\/OLQ.0000000000000972. PMID: 30624309
[3] https:\/\/www.cdc.gov\/std\/treatment-guidelines\/candidiasis.htm<\/a>
[4] Schwebke JR, Nyirjesy P, Dsouza M, Getman D. Vaginitis and risk of sexually transmitted infections: results of a multi-center U.S. clinical study using STI nucleic acid amplification testing. J Clin Microbiol. 2024 Aug 14;62(9):e00816-24
[5]\u00a0 FY24 IQVIA Diagnostics market book
\u00a0<\/p>\n
Phone: +41 61 688 8888 \/ e-mail: media.relations@roche.com<\/p>\n
Phone: +41 79 407 72 58Sileia Urech
Phone: +41 79 935 81 48<\/p>\n
Phone: +41 79 771 05 25Lorena Corfas
Phone: +41 79 568 24 95<\/p>\n
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83<\/p>\n
Phone: +49 172 6367262Yvette Petillon
Phone: +41 79 961 92 50<\/p>\n
Phone: +41 79 205 27 03\u00a0 <\/p>\n
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.comDr Sabine Borngr\u00e4ber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com<\/a><\/p>\n
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com\u00a0 <\/p>\n
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com\u00a0<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/1770978333_273_ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/1770978334_897_F-Hoffmann-La-Roche-Ltd.png\")